Intranasal Ketorolac versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children: A Randomized Clinical Trial

Background: Renal colic is one of the most common complaints among patients referring to the emergency department (ED). Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are gold standards to relieve pain. Objectives: The aim of this study was to evaluate the effects of intranasal Ketamine on pain control versus Ketorolac. Methods: In this randomized clinical trial (RCT), the patients were randomly assigned into two groups. While Ketorolac 30 mg was given intravenously to all patients in the control group, the patients in intervention group received 1 mg/kg drops of Ketamine intranasally. Pain severity, vital signs, and adverse events (AEs) were recorded after 60 min post-dose. Results: A total of 100 patients were enrolled in this study. The mean visual analog scale (VAS) score after the first 5 min was lower in the intranasal Ketamine group compared to control (5 ± 2.26 vs. 8.62 ± 0.49, respectively; P < 0.001), which remained significant at the end of 60th min (P < 0.001). Moreover, additional analgesics administration was higher in intravenous Ketorolac than intranasal Ketamine (22 vs 0%), which was significantly different (P = 0.001). Patients' satisfaction was higher in the intranasal Ketamine group compared to control (3.56 ± 0.35 vs. 1.82 ± 0.98, respectively; P < 0.001). Conclusions: Intranasal Ketamine was beneficial in controlling renal colic-induced pain, which could be prescribed as a treatment instead of normal treatment. It can rapidly improve pain relief in the short term, has lower AEs, and increases the patients' satisfaction.

Download Full-text

Comparison of Levetiracetam and sodium Valproate in the prevention of migraine: a randomized clinical trial study

International Journal of Basic & Clinical Pharmacology ◽

10.18203/2319-2003.ijbcp20183015 ◽

2018 ◽

Vol 7 (8) ◽

pp. 1460

Author(s):

Vahid Abbasi ◽

Abolfazl Atalu ◽

Perham Seddighnia

Keyword(s):

Clinical Trial ◽

Clinical Trials ◽

Randomized Clinical Trial ◽

Statistical Methods ◽

Sodium Valproate ◽

Good Alternative ◽

Migraine Headaches ◽

Neurology Clinic ◽

Prophylactic Use

Background: Sodium valproate is an anti-seizure drug used for prophylactic use of migraine headaches. Despite the efficacy of this drug due to complications that cause some patients to not tolerate the drug. The purpose of this study was to Comparison of levotiracetam and Sodium valproate in migraine prophylaxis.Methods: This is a clinical trials study. 100 migraineurs who referred to the Alavi neurology clinic and indicated the onset of prophylaxis of migraine were studied in two groups of 50, one of which was a group of levetiracetam and another group of sodium valproate Received. Patients received daily 500mg of drug for 3 months and the effect of the drug on the number of attacks, severity of attacks, and MIDAS score was measured. Collected data analyzed by statistical methods in SPSS version 19. P<0.05 was considered as significant.Results: In both cases, significant improvement was observed in the number of attacks, severity and MIDAS score. In all of the criteria, levetiracetam and sodium valproate were almost identical, except for reducing the number of headache attacks that had a significantly in levothyramine group less than sodium valporoste group (P = 0.0001).Conclusions: This study showed that levothyramineacetamin can be used as a good alternative in those who do not tolerate sodium valproate.

Download Full-text